港股異動 | 醫渡科技漲6% 參與開展眼底病變候選藥物III期臨牀項目
格隆匯4月20日丨醫渡科技(2158.HK)漲6.08%,報8.93港元,總市值88億港元。4月13日,醫渡科技宣佈旗下開心生活科技(簡稱“HLT”)與專注於眼科藥物創新研發的港股上市公司兆科眼科攜手,共同開展TAB014第III期臨牀試驗。TAB014是一款眼底病變候選藥物,也是我國首款處於臨牀階段、用於治療濕性老年性黃斑變性(簡稱“wAMD”)患者、基於貝伐單抗的抗體。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.